CU24674B1 - Derivados de fenil-n-quinolina y proceso para su preparación - Google Patents

Derivados de fenil-n-quinolina y proceso para su preparación

Info

Publication number
CU24674B1
CU24674B1 CU2021000006A CU20210006A CU24674B1 CU 24674 B1 CU24674 B1 CU 24674B1 CU 2021000006 A CU2021000006 A CU 2021000006A CU 20210006 A CU20210006 A CU 20210006A CU 24674 B1 CU24674 B1 CU 24674B1
Authority
CU
Cuba
Prior art keywords
group
phenyl
cycloalkyl
preparation
orc
Prior art date
Application number
CU2021000006A
Other languages
English (en)
Other versions
CU20210006A7 (es
Inventor
Cécile Apolit
Florence Mahuteau-Betzer
Romain Najman
Julien Santo
Didier Scherrer
Jamal Tazi
Original Assignee
Abivax
Centre Nat Rech Scient
Inst Curie
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax, Centre Nat Rech Scient, Inst Curie, Univ Montpellier filed Critical Abivax
Publication of CU20210006A7 publication Critical patent/CU20210006A7/es
Publication of CU24674B1 publication Critical patent/CU24674B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>La presente invención se refiere a un compuesto de fórmula (I) o a la sal trifluoroacetato del mismo </p> <p>ESPACIO PARA LA FÓRMULA</p> <p>en donde R3 representa un átomo de cloro o un átomo de hidrógeno, R representa un grupo alquilo (C1-C4), un grupo cicloalquilo (C3-C6), un átomo de halógeno, un grupo alcoxi (C1-C5), un grupo -SO2-NRaRb, un grupo -SO3H, un grupo -OH, un grupo -O-SO2-ORc o un grupo -OP (= O) - (ORc) (ORd), R1 representa (i) un grupo CF3, (ii) un grupo alquilo (C1-C10), (iii) un grupo cicloalquilo (C3-C6) o un grupo heterocicloalquilo (C3-C6) o (iv) un grupo fenilo o un grupo naftilo, y R2 representa un átomo de hidrógeno, un grupo alquilo (C1-C10), un cicloalquilo (C3-C6) o un grupo heterocicloalquilo (C3-C6). La presente invención se refiere además a nuevos compuestos y al proceso de síntesis para manufacturarlos.</p>
CU2021000006A 2018-07-09 2019-07-09 Derivados de fenil-n-quinolina y proceso para su preparación CU24674B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305910.4A EP3594206A1 (en) 2018-07-09 2018-07-09 Phenyl-n-quinoline derivatives for treating a rna virus infection
PCT/EP2019/068459 WO2020011810A1 (en) 2018-07-09 2019-07-09 Phenyl-n-quinoline derivatives for treating a rna virus infection

Publications (2)

Publication Number Publication Date
CU20210006A7 CU20210006A7 (es) 2021-08-06
CU24674B1 true CU24674B1 (es) 2023-08-08

Family

ID=63035966

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000006A CU24674B1 (es) 2018-07-09 2019-07-09 Derivados de fenil-n-quinolina y proceso para su preparación

Country Status (10)

Country Link
US (2) US12084422B2 (es)
EP (2) EP3594206A1 (es)
JP (2) JP7504409B2 (es)
KR (1) KR20210052432A (es)
CN (1) CN112566899B (es)
BR (1) BR112021000331A2 (es)
CA (1) CA3103867A1 (es)
CU (1) CU24674B1 (es)
MX (1) MX2021000089A (es)
WO (1) WO2020011810A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3884946A1 (en) 2020-03-25 2021-09-29 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
MX2022011596A (es) 2020-03-20 2022-10-18 Abivax Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae.
EP3881844A1 (en) 2020-03-20 2021-09-22 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
FR2830862A1 (fr) 2001-10-16 2003-04-18 Lipha Derives nitroso de la diphenylamine a fonction ether ou thioether, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
RU2006108799A (ru) 2003-08-21 2006-07-27 Оси Фармасьютикалз, Инк. (Us) N3-замещенные имидазопиридиновые ингибиторы c-kit
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
ATE435222T1 (de) 2003-12-18 2009-07-15 Tibotec Pharm Ltd Aminobenzimidazole und benzimidazole als inhibitoren der replikation von respiratory syncytial virus
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060069110A1 (en) 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
EP1951704B1 (en) 2005-03-17 2016-03-16 Janssen Sciences Ireland UC 1,3-dihydro-benzimidazol-2-ylidene amines useful for the treatment or prevention of viral infections
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
CN102702194A (zh) 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
FR2901273B1 (fr) 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
US20140187641A1 (en) 2012-08-23 2014-07-03 Gtx Estrogen receptor ligands and methods of use thereof
RU2567752C2 (ru) 2009-06-12 2015-11-10 Абивакс Соединения, пригодные для лечения рака
MY165585A (en) 2010-06-24 2018-04-05 Takeda Pharmaceuticals Co Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
EP2505198A1 (en) 2011-04-01 2012-10-03 Société Splicos Compounds for use as therapeutic agents affecting p53 expression and/or activity
WO2014164667A1 (en) 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
ES2898385T3 (es) * 2013-07-05 2022-03-07 Abivax Compuestos bicíclicos útiles para el tratamiento de enfermedades causadas por retrovirus
RU2628800C2 (ru) 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
HRP20211779T1 (hr) 2016-03-18 2022-03-04 Prosynergia S.A.R.L. Postupak priprave derivata kinolin-2-il-fenilamina i njihovih soli

Also Published As

Publication number Publication date
CU20210006A7 (es) 2021-08-06
CN112566899B (zh) 2024-01-30
EP3594206A1 (en) 2020-01-15
US12084422B2 (en) 2024-09-10
JP2024053563A (ja) 2024-04-15
US20210309611A1 (en) 2021-10-07
BR112021000331A2 (pt) 2021-04-06
US20240308964A1 (en) 2024-09-19
AU2019300100A1 (en) 2021-01-21
KR20210052432A (ko) 2021-05-10
JP7504409B2 (ja) 2024-06-24
WO2020011810A1 (en) 2020-01-16
CA3103867A1 (en) 2020-01-16
CN112566899A (zh) 2021-03-26
MX2021000089A (es) 2021-03-25
EP3820852A1 (en) 2021-05-19
JP2021524481A (ja) 2021-09-13

Similar Documents

Publication Publication Date Title
CU24674B1 (es) Derivados de fenil-n-quinolina y proceso para su preparación
AR086181A2 (es) Metodo para preparar inhibidores macrociclicos inhibidores de serina proteasas del virus de la hepatitis c
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
EA201170096A1 (ru) Замещенные производные пиримидона
CY1118435T1 (el) Παραγωγο μορφολινο νουκλεϊνικου οξεος
DOP2011000061A (es) Compuestos de pirrol
CY1123514T1 (el) Κρυσταλλικο 2-φθορο-3-νιτροτολουολιο και διαδικασια για την παρασκευη του
CL2012000003A1 (es) Compuestos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida sustituida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y uso de dichos compuestos como inhibidores de fosforilacion de akt (pkb) para el tratamiento del cancer.
CU20100021A7 (es) Derivado de oxopirazina y herbicida
NI201000150A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización.
ES2587284T3 (es) 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
AR087148A1 (es) Imidazopiridazinas
AR103742A1 (es) Derivados de trifluorometilpropanamida
CY1116875T1 (el) Διϋδροετορφινες και η παρασκευη αυτων
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
ES2722431T3 (es) Novedosos compuestos de aril-cianoguanidina
CO6251363A2 (es) Derivados de indol-2-ona disustituidos en 3 su preparacion y su aplicacion en terapeutica
AR054849A1 (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
BR112022002674A2 (pt) Derivado de 2-aminoquinazolinona
AR122781A1 (es) Procesos para elaborar compuestos serd tricíclicos que tienen un resto sustituido de fenilo o piridinilo
CO6251285A2 (es) Derivado de tetrahidroisoquinolina novedoso
SA520412408B1 (ar) عملية تحضير مركبات ثنائي أريل أوكسي بنزو ديازول غير متجانسة مزدوجة الاستبدال
UY39789A (es) Intermedio novedoso para la preparación de piroxasulfona.
BR112019001015A2 (pt) composto de benzilamida, método para produção do mesmo, e miticida